On November 18, 2019, as a result of the advocacy of CLSA’s Washington, D.C. based team and the leadership of Congressman Lou Correa (D-Santa Ana), a California Democratic Delegation letter was sent to House Leadership urging swift action to repeal the medical device tax before the end of the year.
Looking ahead at 2020, we anticipate a ballot crowded with initiatives, many of which could have a significant impact on California’s life sciences industry. The issues being covered range from consumer privacy, which we have previously discussed at length, to commercial property taxes and funding for California’s stem cell agency.
CLSA recently released the findings of a CLSA-commissioned study, conducted by international health economics firm Vital Transformation, to examine the impact of using international reference pricing in Medicare Part D (as proposed in H.R. 3, the Lower Drug Costs Now Act of 2019) on California’s innovative biotechnology sector.
The enactment of the California Consumer Privacy Act of 2018 (AB 375) (CCPA) brought sweeping restrictions on the collection and use of consumer information. A clean-up bill that same year, SB 1121 (Dodd), added key exceptions to the CCPA to help protect clinical trials and other biomedical research from unintended consequences, including exceptions for, among other things, protected health information (PHI) under federal law and information collected as part of a clinical trial subject to various laws and guidelines.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, today announced the expansion of its board of directors, adding three new members. Joining the board are: Mohit Trikha, Ph.D., Vice President, Head of Oncology Early Development & AbbVie Bay Area Site Head; Lesley Stolz, Ph.D., Managing Director, Lasana Partners; and Grace Han McMahon, Head of Transactions, Pacific Innovation Hub, Business Development & Licensing, Merck Research Laboratories.
CLSA’s HR 3 impact study was featured in this high-profile STAT News article, highlighting the impact that the drug pricing proposal (HR 3) would have on small and emerging biotechnology companies in California.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, invites members of the press to attend the 2019 CLSA Pantheon DiNATM Awards, a distinguished program that honors and recognizes the impact that California’s therapeutic, diagnostic, medical device, and industrial biotechnology companies are making in California and for patients around the globe
California Life Sciences Association was recently featured in the San Diego Union-Tribune regarding its new study on the impact of international reference pricing. Up to 88 percent fewer new drug approvals projected in study commissioned by Biocom and California Life Sciences Association.
California Life Sciences Association (CLSA) was recently featured in the San Diego Business Journal commenting on changes by California regulatory agencies that impact Association health plans, including CLSA’s Benefits Advantage Trust plan for small businesses.
California Life Sciences Association President & CEO Mike Guerra was recently profiled by the San Francisco Business Times. Learn about the association’s priorities, Mike’s background and more.